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The  association  of cystatin  C with  renal  function  has been  studied  for more  than  25 years.  Cystatin  C
has  been  described  to have  a better  diagnostic  performance  than  creatinine  to  assess  renal  function,
particularly  to detect  small  reductions  in  glomerular  ﬁltration  rate.  Recently,  cystatin  C has  emerged  as a
strong  predictor  of incident  or recurrent  cardiovascular  events  and  adverse  outcomes  in patients  without





to  both  inﬂammation  and  atherosclerosis.  Nevertheless,  the link  between  inﬂammation,  atherogenesis,
cardiovascular  risk,  and  cystatin  C  is still poorly  understood.  This  brief  report  discusses  recent  data,
contrasting  ﬁndings  and  possible  mechanisms  involved  in  this  interaction.
©  2013  Japanese  College  of Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.idney disease
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ntroduction
Cystatin C, a member of the human cystatin superfamily, is the
ost abundant and potent inhibitor of cysteine proteases. Cystatin
 is a low molecular mass protein (13.4 kDa) that is freely ﬁltered at
he glomerulus and then reabsorbed and fully catabolized, but not
ecreted, by proximal renal tubules. In the past few years, cystatin
 has been proposed as a more reliable marker of renal function
mortality among elderly persons with chronic kidney disease (CKD)
or without renal impairment [2]. However, the postulated role of
cystatin C as a marker of inﬂammation and atherosclerosis has been
controversial. In this setting, we would like to draw attention to
some studies with contrasting ﬁndings in the literature, with regard
to the association of cystatin C with atherosclerosis, cardiovascular
disease, and inﬂammation.han serum creatinine [1]. Additionally, serum cystatin C has been
eported not only as a marker of glomerular ﬁltration rate (GFR), but
lso as an independent risk factor for all-cause and cardiovascular
∗ Corresponding author. Tel.: +55 98 81427606; fax: +55 98 32320286.
E-mail address: jvlsalgado@yahoo.com.br (J.V. Salgado).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.05.015Decreased cystatin C levels and cardiovascular disease
The pathogenesis of atherosclerosis and abdominal aortic
aneurysm (AAA) involves substantial proteolysis of the extracel-
lular matrix architecture of the arterial wall. The participation has
been reported of matrix metalloproteinases, serine, and lysosomal
cysteine proteases in extensive extracellular matrix degradation
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nd vascular wall remodeling. Atherosclerotic lesions in humans
ave shown an overexpression of elastolytic and collagenolytic
ysteine proteases (cathepsins S, K, B, H, and L) and a decreased
xpression of cystatin C, their most abundant extracellular inhibitor
3–5]. There is also markedly increased expression of the vari-
us cathepsins within the AAA wall compared to healthy aorta.
oreover, weak overall expression of cystatin C was  observed by
mmunohistochemistry in all the cells localized in the AAA with the
xception of the luminal endothelial cells [6].
In this context, Shi et al. [7] found reduced cystatin C in
oth atherosclerotic and aneurysmal aortic lesions, but normally
xpressed in vascular wall cells. Increased abdominal aortic diam-
ter among 122 patients screened by ultrasonography correlated
nversely with serum cystatin C levels, although only 8 patients
ith dilated aorta had lower serum cystatin C than patients with
ormal aorta. Similarly, Lindholt et al. [8] showed that the serum
evel of cystatin C was negatively correlated with AAA size and
rogression. However, C-reactive protein and renal function were
ot associated with AAA expansion, suggesting that the correlation
etween cystatin C and expansion may  be a result of the extracel-
ular inhibition of proteases. Of note, decreased plasma cystatin C
evels have been shown in patients with coronary artery ectasia
oexisting with obstructive coronary artery disease (CAD), when
ompared to patients with obstructive CAD alone. Furthermore,
atients with AAA were shown to have lower cystatin C levels as
ompared to patients with obstructive abdominal aortic disease
3].
In the past decade, many groups have assessed the effect of
ystatin C on plaque formation. Sukhova et al. [9] showed that
therosclerotic mice (ApoE−/−/CysC−/−)  deﬁcient in cystatin C
nd apolipoprotein E displayed increased tunica media elastic lam-
na degradation, smooth muscle cells accumulation, and collagen
ontent, but no difference in the size of aortic lesions induced by
n atherogenic high-cholesterol diet. Similarly, Bengtsson et al. [10]
eported increased plaque size and macrophage content in the dou-
le knockout mice (ApoE−/−/CysC−/−) when fed a high-fat diet.
Evidence suggests that reactive oxygen species contribute to
ascular oxidative stress, inﬂammation, and endothelial dysfunc-
ion, which have a very important role in atherogenesis and heart
ailure [11]. Interestingly, Xie and colleagues showed that H2O2
reatment causes elevation of cystatin C in the conditioned medium
rom cardiomyocytes. When cardiomyopathy was induced in mice
y chronic administration of doxorubicin, elevated cystatin C pro-
ein was detected in the plasma and the myocardium. Thus, the
uthors suggested that cystatin C plays a role in cardiac extracellu-
ar matrix remodeling [12].
A recent experimental study demonstrated that enhanced cys-
eine protease activity, due to the lack of cystatin C, favors
nﬂammation in AAA lesions induced in atherosclerotic mice by
romoting microvascularization and smooth muscle cell apoptosis
s well as leukocyte adhesion and proliferation [13]. In addition,
ow cystatin C levels seem to reduce resistance to bacterial and viral
nfection, thus potentially enhancing chronic low-grade inﬂamma-
ory stimuli responsible for aggressive plaque growth [14].
Some investigators have also examined the inﬂuence of func-
ional polymorphisms in cystatin C gene expression in order to
lucidate the signiﬁcance of cystatin C in pathological vascular
emodeling in vivo. In this setting, Eriksson et al. [15] showed an
ssociation between a genetically determined decrease in cystatin
 expression with increased severity of CAD. The mutant cystatin C
aplotype was associated with a greater number of coronary artery
tenoses and serum cystatin C levels were lower in postinfarction
atients than in controls. In this study, it was possible to observe
hat, despite genetic variation in cystatin C gene expression, serum
ystatin C values were found within the normal reference range
n all subjects studied. Of interest, the cystatin C gene is of theiology 62 (2013) 331–335
housekeeping type, which indicates a stable production rate of
cystatin C by most nucleated cell types [2].
Conversely, Eriksson et al. [16] have identiﬁed a weak associ-
ation between variation in the cystatin C gene and AAA growth,
maintained after adjustment for aneurysm diameter and smok-
ing, both of which inﬂuence aneurysm growth. In addition, Albert
et al. reported no association between baseline cystatin C levels
and increased risk of future peripheral arterial disease in healthy
subjects who were in the early stage of atherosclerosis. They found
that median plasma levels of cystatin C were identical in the case
and control groups. Henceforth, the authors hypothesized that,
unlike interleukin-6, C-reactive protein, and intercellular adhe-
sion molecule-1, reduced baseline levels of cystatin C in healthy
subjects might contribute to increased systemic atherosclerosis
[17].
Increased cystatin C levels and cardiovascular disease
Contrary to these ﬁndings, Salgado et al. have found a signiﬁcant
correlation between high serum cystatin C levels and cardiovas-
cular risk factors in primary hypertensive patients [18]. Likewise,
several epidemiological studies consistently report a positive and
graded association between higher serum cystatin C levels and
increased cardiovascular disease prevalence in individuals with
GFR ≥60 ml/min/1.73 m2 (Fig. 1) [19].
A recent study conducted by Urbonaviciene et al. [20] demon-
strated that higher serum cystatin C levels independently predicted
5-year all-cause and cardiovascular mortality in symptomatic
peripheral arterial disease patients with normal renal function.
In accordance with Urbonaviciene et al. [20], Loew and col-
leagues [21] have reported that only high plasma cystatin C levels
(>1.24 mg/l) were associated with risk of fatal and nonfatal car-
diovascular events during the follow-up. Furthermore, in a recent
meta-analysis, higher cystatin C levels were strongly and indepen-
dently associated with speciﬁc endpoints like stroke, myocardial
infarction and heart failure [22].
In contrast to Eriksson et al. [15], Loew and colleagues [21]
reported that the cystatin C haplotype alone was not associated
with prognosis of coronary heart disease and a moderate variation
in mean cystatin C levels was found between the various genotype
groups [21]. It was also reported that plasma cystatin C was sig-
niﬁcantly higher in the unstable angina group than in the stable
angina group. Plasma cystatin C positively correlated with plaque
area and plaque burden in the unstable angina group but not in
the stable angina group. In this study, higher plasma cystatin C
levels suggested the presence of larger atherosclerotic extent in
plaques in unstable angina patients [23]. Batra et al. [24] carried
out a prospective study on 150 Indian patients undergoing coro-
nary angiography. The authors found that higher plasma cystatin
C levels were associated with higher carotid intimal medial thick-
ness, diffuse CAD, and more frequent occurrence of triple vessel
disease. The association of high cystatin C levels with CAD remained
robust even in those patients with normal or mildly impaired renal
function.
Of note, Imai et al. [25] demonstrated that higher serum
cystatin C concentrations were correlated with early stage coro-
nary atherosclerosis plaques among patients without established
chronic kidney dysfunction. The results further suggest that non-
calciﬁed plaques are more strongly associated with serum cystatin
C levels than calciﬁed plaques. In addition, the risk for presence
of noncalciﬁed plaques increased with the increasing quartiles
of cystatin C, independent of GFR and other cardiovascular risk
factors. The authors also assumed that adverse cardiovascular
events may  derive from involvement of cystatin C in early-stage


























wFig. 1. Controversial ﬁndings regarding the relati
oronary plaque formation even in those patients with estimated
FR ≥60 ml/min/1.73 m2 [25].
In agreement with previous authors, Niccoli et al. [26]
emonstrated that in patients with CAD and with normal
reatinine-derived GFR, increased serum cystatin C levels are asso-
iated with a stable lesion phenotype and independently predict
xtent of coronary atherosclerotic burden. This study suggests that
he association between cystatin C and risk of cardiovascular events
s mediated by an increased coronary atherosclerotic burden. In
greement with Niccoli et al. [26], we assume that the association
f serum cystatin C levels with severity-extent of CAD might be
ediated by impaired kidney function, since cystatin C is a more
ensitive marker than creatinine-based parameters in the assess-
ent of GFR.
Cystatin C predicts mortality risk in subjects with established
eart failure better than serum creatinine level or estimated
FR [27]. Astor and colleagues [28] have demonstrated that 2-
icroglobulin and, to a lesser extent, -trace protein levels share
ystatin C’s advantage over serum creatinine-based estimated GFR
alculated using the Chronic Kidney Disease Epidemiology Collab-
ration (CKD-EPI) equation in predicting mortality, coronary heart
isease, heart failure, and kidney failure.
Conﬂicting reports have also been published on the correlation
etween cystatin C and markers of subclinical atherosclerosis such
s carotid intima media thickness (IMT) and ﬂow-mediated dilation
f brachial artery (FMD) [29,30]. Additionally, a recently published
tudy has demonstrated no signiﬁcant correlation of cystatin C
ith carotid intima media thickness, ﬂow-mediated dilation of between cystatin C and cardiovascular diseases.
brachial artery and inﬂammatory markers such as high-sensitivity
C-reactive protein and ﬁbrinogen [31].
Cystatin C, inﬂammation and early kidney dysfunction
As far as we are concerned, the mechanism of the association
between high serum cystatin C levels and cardiovascular events
is largely unknown and hypothetical, it is assumed to represent
early kidney disease. On the other hand, the adverse effect of higher
cystatin C in patients with cardiovascular diseases is not yet com-
pletely explained by the renal dysfunction. In this respect, large
cohort studies have reported a signiﬁcant association between high
cystatin C concentrations and C-reactive protein with a higher inci-
dence of cardiovascular events and premature death in elderly
populations [32]. Accordingly, Urbonaviciene et al. [20] found a sig-
niﬁcant correlation of cystatin C with high-sensitivity C-reactive
protein and also suggested that cystatin C might capture an associ-
ation of mild renal dysfunction with increased chronic low-grade
inﬂammation [20]. It has been suggested that cystatin C would be a
marker of both inﬂammation and renal function. Thus, atherogenic
changes associated with inﬂammation could be one mechanism
associated with cystatin C and cardiovascular disease [33,34].
Nevertheless, in large cohort studies, the signiﬁcant association
found between cystatin C and inﬂammation (C-reactive protein)
does not mean a causal relationship between them [32]. From our
perspective, this association is expected, as inﬂammation is acti-
vated in early phases of renal disease [2]. Moreover, as we have
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eductions in renal function that may  identify a preclinical stage
f kidney disease [35,36]. In this context, we believe that cystatin
 could directly reﬂect this association with more sensitivity than
erum creatinine or estimated creatinine clearance [2]. It is well
nown that cystatin C is less inﬂuenced by age, gender, race, muscle
ass, drug administration, physical activity, and diet as compared
o creatinine [24,26].
Previous studies have found no association between cystatin
 and C-reactive protein when adjusting for kidney function and
ther studies reported a correlation between C-reactive protein and
ystatin C levels in patients not affected by CAD. Recently, Grubb
t al. [32] showed that the inﬂammatory status of a patient does
ot inﬂuence the role of cystatin C as a marker of GFR and Niccoli
t al. [26] assumed that an inﬂammatory mechanism does not seem
o be involved in the association between cystatin C and coronary
therosclerosis.
It is noteworthy that most studies reporting association of cys-
atin C levels with cardiovascular events in patients with normal
enal function lacked gold standard measurements of GFR. These
tudies have compared cystatin C with creatinine or estimated GFR,
hich are not able to fully adjust for true renal function. To date,
t seems plausible that the superiority of serum cystatin C over
erum creatinine for predicting cardiovascular events and adverse
utcomes is related to its properties as a marker of kidney func-
ion.
Recently, the KDIGO (Kidney Disease: Improving Global Out-
omes) CKD Work Group recommended measuring serum cystatin
 as a conﬁrmatory test for the diagnosis of CKD in adults patients
ith a decreased GFR as estimated from creatinine [37]. Patients
ith CKD have higher risks for all-cause mortality, cardiovascular
vents, and end-stage renal disease. Hence, cystatin C could also be
sed as a screening tool for occult CKD (i.e. missed by creatinine)
n high-risk individuals [38]. Interestingly, the European Society of
ardiology also recommended the prognostic use of cystatin C in
yocardial infarction (MI) and in the detection of long-term risks
f death of patients with non-ST-segment elevation acute coronary
yndrome [39].
erspectives
There are many possible explanations for the discrepancy
etween the tissue and circulating cystatin C levels. Considering the
nti-atherogenic role of cystatin C, an imbalance between cysteine
roteases and cystatin C would favor positive arterial remodeling
3]. On the other hand, the existence of a balance between cys-
eine proteases and their inhibitor cystatin C at the level of arteries
nd in circulation would offer protection against atherosclerosis
nd future cardiovascular events. A study in humans indicated
hat statin therapy decreased proteolytic activity by reducing
atrix metalloproteinase (MMP)-9, MMP-3, cathepsins H and L,
nd increasing cystatin C levels in the wall of AAAs [40]. Unlike the
revious study, other researchers have reported that statin treat-
ent did not inﬂuence the serum levels of cystatin C, but decreased
he activity of MMPs [41].
Moreover, there is a consumption theory of circulating cystatin C
n which low levels of this protein could be explained by its overuse
gainst the surge in proteolytic activity. Another possible mecha-
ism responsible for lower levels of serum cystatin C may  be its
hronic overuse through increased coronary atherosclerotic bur-
en. Subsequently, as a consequence of low cystatin C levels, an
ncreased elastolytic activity of cathepsins would result in rapid
egradation and progression of atherosclerotic plaques [41].In contrast, the relationship between elevated cystatin C level
nd cardiovascular damage may  reﬂect an attempt to counter-
alance a potentially damaging increased elastolytic activity [20].
igher plasma cystatin C would result from cytokine-stimulatediology 62 (2013) 331–335
cells, which release cystatin C into circulation in the process of
atherosclerosis and compensate for the decreased cystatin C in
plaques [23]. Other authors have also suggested that serum cys-
tatin C levels might be increased during an inﬂammatory process
in vulnerable plaque preceding and occurring along with the index
cardiovascular or cerebrovascular event. Thereafter, cystatin C lev-
els would return to baseline levels with the recovery of the index
event or calming down of plaque vulnerability [41].
In the light of this information, it was assumed that cystatin C
would have a dynamic physiology whose values may differ depend-
ing upon whether the CAD is acute or chronic. For instance, high
levels of cystatin C may  raise the suspicion of non-ST-segment
elevation acute coronary syndrome whereas lower cystatin C lev-
els in a clinically stable patient would reﬂect a greater and stable
atherosclerotic burden [26,41].
Nevertheless, there is also evidence that systemic pro-
inﬂammatory factors, pro-thrombotic mediators, cytokines, and
adipokines are intimately linked to the genesis of insulin resis-
tance, metabolic syndrome, type 2 diabetes, atherosclerosis, and
hypertension. These physiologic processes have been connected
with end-organ damage, incident CKD, high cystatin C levels, and
consequently higher cardiovascular risk and all-cause mortality
[33,36,42].
Besides, CKD promotes hypertension, dyslipidemia, oxidative
stress, and systemic inﬂammation, which in turn can contribute
to the development of endothelial dysfunction and progression of
atherosclerosis [43]. Hence, cystatin C can detect a slight decrease in
kidney function, which even within the normal range may  promote
arteriosclerosis. Likewise, a very mild kidney dysfunction caused by
atherosclerosis could be detected by cystatin C.
It is also known that heart failure patients have a high prevalence
of renal insufﬁciency with worse prognosis [44]. This bidirectional
heart–kidney interaction leads to a “vicious circle” and occurs at
several levels through various pathways affecting hemodynamics,
neurohumoral signaling, as well as salt and water homeosta-
sis. Although the normal physiology of the heart and kidney is
well characterized, pathophysiological changes and mechanisms of
organ dysfunction related to the cardiorenal syndrome are poorly
understood [45].
Taking all ﬁndings into consideration, we  would propose differ-
ent roles for cystatin C in the circulation and in the plaque. Owing to
its stable production rate and contrasting patterns recently demon-
strated in vivo [46] and in vitro [47], we raise the hypothesis that
cystatin C might have limited and localized actions over cysteine
proteases in vessel walls, which in its turn would not have inﬂuence
over its systemic concentrations. Instead of compromising its use
in clinical practice, the so called “non-GFR determinants” [48,49]
of cystatin C might concede to this marker the ability to recog-
nize the effects of the systemic interactions on kidney function
better than serum creatinine and even than direct measurements
of GFR.
Conclusion
Further clinical and experimental studies are certainly required
to answer the assumptions raised here. Nevertheless, as reviewed
here, cystatin C can provide novel insights into the patho-
physiologic mechanisms of the cardiorenal metabolic syndrome.
Consistent with prior reports, cystatin C can contribute to cardio-
vascular risk stratiﬁcation as well as to its prevention. Estimated
GFR based on cystatin C could also be useful to conﬁrm an adverse
prognosis in patients with CKD. Future research studies should
investigate the inclusion of cystatin C in models for predicting risk
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